KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity

Home KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity

KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity

/ Publications

Share the Post

About the Author

Related Posts

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH
Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Comments

Comments are closed.